Drug development company Noxopharm (ASX:NOX) has treated its first prostate patient in its LUPIN study at St Vincent’s hospital in Sydney.
The clinical trial is testing the safely and efficacy of an anti-cancer drug formulation, NOX66, combined with a prostate specific membrane antigen, LuPSMA, in men with prostate cancer who have been resistant to all other therapies and have limited survival prospects.
LuPSMA has emerged as a promising experimental treatment for late-stage prostate cancer, with clinical studies showing a 50 per cent success rate in patients responding to the treatment.
The treatment results in shrinkage or complete remission of the cancer, however the response to LuPSMA typically lasts less than 12 months.
The company said there is a need to extend the response time and to increase the proportion of patients who respond positively to the treatment.
Shares in Noxopharm (ASX:NOX) are trading 3.15 per cent higher to 66 cents.